The report, dubbed "JNC VI," goes further than its predecessors in its scope and in basing its treatment recommendations on scientific evidence. Although many of its recommendations arose from extensive published findings, the new report is a consensus of the nation's experts in the treatment of hypertension, and will define the standard of care for hypertension for the next several years.
Among the key recommendations:
• A blood pressure of 140/90 mm Hg is no longer the target blood pressure for everyone. Patients with heart failure, diabetes mellitus, or renal insufficiency are candidates for immediate treatment with antihypertensive drugs and lifestyle modifications even if their blood pressures are as low as 130/85.
• For patients without serious risk factors but with blood pressure in the high-normal range of 130/85 to 139/89 mm Hg, physicians should be more aggressive in prescribing lifestyle modifications (weight loss, increased exercise, and reduced alcohol and salt intake) to lower the blood pressure to less than 130/85.
The new report still recommends diuretics and beta-blockers as initial drug choices for uncomplicated hypertension. However, it also recommends certain additional drug classes when hypertensive patients have diabetes, heart failure, or isolated systolic hypertension.
• PHYSICIANS ARE UNDERTREATING HYPERTENSION
The new recommendations are more aggressive partly because there is disturbing evidence that we are undertreating hypertension. From 1972 until 1992, the rates of hypertension-related morbidity and mortality declined dramatically. However, since then, progress seems to be slowing or even regressing. For example:
• Age-adjusted stroke rates have risen slightly since 1993, while the age-adjusted rate of coronary heart disease has remained stable. 2 • The incidence of end-stage renal disease is increasing. (Hypertension is the second most common cause of renal failure, after diabetes.) 3 • The incidence of heart failure is increasing, especially in elderly patients. (The great majority of heart failure patients have antecedent hypertension. ) 4 • Today, fewer persons with hypertension are aware of it, receive treatment for it, and have it under control compared with 5 or 6 years ago. In 1991 through 1994, the National Health and Nutrition Examination Survey estimated that only 27.4% of persons with hypertension had their blood pressure controlled to the recommended level of less than 140/90 mm Hg. By comparison, the figure was 29% in 1988-1991 (an increase from 10% in 1976-1980). 5 These trends indicate a need for intensified education for both health-care professionals and the public. In particular, the JNC VI report calls for Americans to pursue a healthier lifestyle that would lead to a lower prevalence of hypertension and cardiovascular disease, and says that preventing and treating hypertension will be a major public health challenge in the new millennium. 6 A point not stated explicitly in the JNC VI report but which I believe is important: physicians should not accept less-than-optimal results when treating high blood pressure. If a patient begins with a blood pressure of approximately 180/110 mm Hg, and with treatment succeeds in lowering it to approximately 150/100 mm Hg, many physicians would be satisfied. But 150/100 is still too high. The JNC VI report says: "The goal of prevention and management of hypertension is to reduce morbidity and mortality by the least intrusive means possible. This may be accomplished by achieving and maintaining systolic blood pressure below 140 mm Hg and diastolic blood pressure below 90 mm Hg and lower if tolerated, while controlling other modifiable risk factors for cardiovascular disease. Treatment to lower levels may be useful, particularly to prevent stroke, to preserve renal function, and to prevent or slow heart failure progression." Risk group B consists of persons with at least one additional risk factor (not including diabetes), but no target organ damage or clinical cardiovascular disease. Persons in this group with stage 1 hypertension can try lifestyle modification alone for up to 6 months if they have only one risk factor. Patients with higher blood pressure or with more than one risk factor should begin lifestyle modification and drug therapy immediately.
• URGENCY OF DRUG TREATMENT DEPENDS ON LEVEL OF RISK
Risk group C has the highest risk: target organ damage, clinical cardiovascular disease, or diabetes, with or without other risk factors.
As stated above, persons with heart failure, diabetes, or kidney failure should begin lifestyle modification and drug therapy immediately, even if their blood pressure is in the high-normal range of 130/85 to 139/89 mm Hg.
• DRUG THERAPY RECOMMENDATIONS Initiating drug therapy Like the previous report, issued in 1993, 7 the JNC VI report recommends diuretics or betablockers as initial drug choices for hypertension that is not complicated by concomitant diseases. These are still the only classes of drugs proven in large-scale clinical trials to decrease morbidity and mortality ( In a departure from the previous report, the JNC VI report emphasizes four compelling indications for using other classes of drugs (TABLE 3) :
Type 1 diabetes mellitus with proteinuria: Angiotensin-converting enzyme (ACE) inhibitors are indicated.
Heart failure due to systolic dysfunction: ACE inhibitors and diuretics are indicated.
Isolated systolic hypertension in older patients: Diuretics are preferred, but long-acting dihydropyridine calcium antagonists may also be indicated.
Postmyocardial infarction: Beta-blockers without intrinsic sympathomimetic activity (TABLE 3) are indicated; ACE inhibitors are indicated for patients with systolic dysfunction.
The report also identifies several less compelling indications, and some relative contraindications, for specific classes of drugs (TABLE 3) .
Adjusting drug therapy
If the initial drug at a full dose has no effect on the blood pressure or causes troublesome side effects, JNC VI recommends substituting a drug from a different class. However, if the initial drug produces only a partial response but is tolerated well, JNC VI recommends adding another drug from a different class, preferably a diuretic if not already used (TABLE 2) . The point, in my experience, is to avoid substituting one drug after another ("sequential monotherapy") in a frustrating and futile search for a single, ideal drug to control the patient's blood pressure. Patients become dissatisfied with this approach and either drop out of therapy or consult another physician.
• CHALLENGE TO MANAGED CARE: SAVE MONEY BY CONTROLLING HYPERTENSION
Treating high blood pressure is expensive, but in the long run it costs less than treating the consequences of hypertension: heart disease, stroke, and renal failure. [9] [10] [11] Herein lies an opportunity for managed care organizations, which have a vested interest in keeping their patients healthy. The JNC VI report suggests that managed care organizations could "...use a coordinated approach to care, using various health care professionals and featuring an appropriate frequency of office visits, short waiting times, supportive patient counseling, and controlled formularies." By so doing, they could avoid many hospitalizations, surgical procedures, and use of expensive technology.
The role of hypertension specialists, the report says, will be to provide cost-effective care by adapting national guidelines for local care, by providing guidance for using new drugs and diagnostic procedures, and by managing patients with resistant hypertension, secondary hypertension, and complex concomitant conditions.
• EVIDENCE-BASED APPROACH TO HYPERTENSION MANAGEMENT
The new JNC report, more than earlier reports, references the published studies from which each prevention or treatment recommendation emanated. Codes next to the references in the section of the JNC VI report on prevention and treatment specify what kind of data is the basis for the recommendation (meta-analysis, randomized controlled trial, retrospective analysis, prospective follow-up study, cross-sectional population study, review or position statements, and nonrandomized clinical interventions).
Shortcomings of randomized controlled trials
Where possible, the committee tried to base its recommendations on randomized controlled trials. Nonetheless, as the report notes, this approach has its limitations. For instance, randomized controlled trials are of short to moderate duration, whereas the benefit of hypertension treatment accrues over a lifetime. Most do not include a true placebo group, thus underestimating the benefit of the trial. Most do not truly represent clinical practice because some patients, typically those at higher risk, are excluded. The average reduction in blood pressure in clinical trials is modest and underestimates the additional benefits that accrue from larger decreases in blood pressure, which may be seen in individual patients.
Trials focus on predetermined endpoints and not necessarily on other benefits of therapy such as improved quality of life, reduced impact of comorbid conditions, fewer workdays missed due to illness, and prevention of progression to disease endpoints.
Thus, in making their recommendations, the JNC VI members stated that they "extrapolated the treatment effects beyond the duration of clinical trials, based on physiological and epidemiological data." 1 This need to extrapolate beyond existing evidence underscores the evolving state of hypertension treatment and the interplay between the science and the art of medicine.
• THE PRIMARY MESSAGE OF JNC VI
The most important message of JNC VI, however, is the simplest one, that despite our knowledge of the long-term beneficial effects of treating hypertension, much remains to be done until Americans are treated properly for this potentially devastating condition. H
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